Keryx Biopharma (KERX) Misses Q4 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 inches lower as Middle East tensions outweigh tech gains
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
FBR Capital Upgrades Keryx Biopharmaceuticals (KERX) to Outperform
February 29, 2016 6:48 AM ESTFBR Capital upgraded Keryx Biopharmaceuticals (NASDAQ: KERX) from Market Perform to Outperform with a price target of $10.00.
Analyst Christopher James commented, "We are upgrading KERX shares to Outperform from Market Perform, based on our valuation of the shares relative to current price levels, and maintaining our current price target of $10. On February 25, Keryx... More
Raymond James Upgrades Keryx Biopharmaceuticals (KERX) to Outperform
February 26, 2016 7:10 AM ESTRaymond James upgraded Keryx Biopharmaceuticals (NASDAQ: KERX) from Market Perform to Outperform with a price target of $6.00.
For an analyst ratings summary and ratings history on Keryx Biopharmaceuticals click here. For more ratings news on Keryx Biopharmaceuticals click here.
Shares of Keryx Biopharmaceuticals closed at $3.34 yesterday.
... MoreJPMorgan Downgrades Keryx Biopharmaceuticals (KERX) to Neutral
February 26, 2016 7:09 AM ESTJPMorgan downgraded Keryx Biopharmaceuticals (NASDAQ: KERX) from Overweight to Neutral and removed its price target (prior $11.00).
For an analyst ratings summary and ratings history on Keryx Biopharmaceuticals click here. For more ratings news on Keryx Biopharmaceuticals click here.
Shares of Keryx Biopharmaceuticals closed at $3.34 yesterday.
... More